Embracing novel cytokines in RA – complexity grows as does opportunity!

Hueber, A.J., Asquith, D.L., McInnes, I.B. and Miller, A.M. (2010) Embracing novel cytokines in RA – complexity grows as does opportunity! Best Practice and Research: Clinical Rheumatology, 24(4), pp. 479-487. (doi:10.1016/j.berh.2010.01.004) (PMID:20732646)

Full text not currently available from Enlighten.

Abstract

Current therapeutics for the treatment of rheumatoid arthritis (RA) offer limited efficacy in a restricted number of patients. There is, therefore, an unmet clinical need for the development of more efficacious therapeutics for the treatment of disease. Anti-TNF alpha. therapy has provided proof of principle that cytokine blockade is an appropriate strategy by which to inhibit disease progression. In this review, we describe the basic biology of potential novel cytokine targets and the results of recent clinical trials, with particular focus on the cytokines related to Th17 biology, namely interleukin (IL)-12, IL-23 and IL-17, in addition to the TNF superfamily and the adipocytokines.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:McInnes, Professor Iain and Asquith, Dr Darren and Miller, Dr Ashley and Hueber, Dr Axel
Authors: Hueber, A.J., Asquith, D.L., McInnes, I.B., and Miller, A.M.
College/School:College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
Journal Name:Best Practice and Research: Clinical Rheumatology
ISSN:1521-6942
ISSN (Online):1532-1770

University Staff: Request a correction | Enlighten Editors: Update this record